Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Stifano, Giuseppina ^a   Affandi, Alsya J ^a,b   Mathes, Allison L ^a   Rice, Lisa M ^a   Nakerakanti, Sashidhar ^a   Nazari, Banafsheh ^a   Lee, Jungeun ^a   Christmann, Romy B ^a   Lafyatis, Robert ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; CD14 ANTIGEN; CELL MARKER; ENDOTOXIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YM1 PROTEIN; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE; TRANSCRIPTOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA MODIFIED RODNAN SKIN SCORE; DERMATITIS; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MALE; MOUSE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN DEFECT; SKIN FIBROSIS; SKIN STIMULATION; SYSTEMIC SCLEROSIS; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; FIBROSIS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; PATHOLOGY; SKIN;

ANIMALS; FIBROSIS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN; TOLL-LIKE RECEPTOR 4; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905247530     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4598     Document Type: Article

References (39)

1. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, Choquette D, Raymond Y, Senecal JL. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001, 44:735-736.
2. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332.
3. Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, Stifano G, Lafyatis R. Thymic stromal lymphopoietin is Up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor beta. Arthritis Rheum 2013, 65:1335-1346.
4. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001, 276:10594-10601.
5. Meyer M, Muller AK, Yang J, Sulcova J, Werner S. The role of chronic inflammation in cutaneous fibrosis: fibroblast growth factor receptor deficiency in keratinocytes as an example. J Investig Dermatol Symp Proc 2011, 15:48-52.
6. Granel B, Chevillard C, Allanore Y, Arnaud V, Cabantous S, Marquet S, Weiller PJ, Durand JM, Harle JR, Grange C, Frances Y, Berbis P, Gaudart J, de Micco P, Kahan A, Dessein A. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006, 58:693-699.
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
8. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
9. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
10. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
11. Kobayashi T, Takahashi K, Nagai Y, Shibata T, Otani M, Izui S, Akira S, Gotoh Y, Kiyono H, Miyake K. Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice. Int Immunol 2008, 20:881-891.
12. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008, 20:420-425.
13. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 2002, 277:47834-47843.
14. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992, 176:1665-1671.
15. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002, 23:301-304.
16. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
17. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, Lafyatis R, Radstake T, Feghali-Bostwick C, Varga J. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013, 182:192-205.
18. Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR, Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 2011, 168:e61-e69.
19. Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010, 2010:192543.
20. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13:1324-1332.
21. Masi AT, . Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
22. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
23. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998, 25:84-88.
24. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150.
25. Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, Eberhart CG, Dubuc A, Guettouche T, Cardentey Y, Marra M, Malkin D, Rutka JT, Korshunov A, Pfister S, Taylor MD. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2011, 123:615-626.
26. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, Wigley F, Medsger T, Steen V, Moreland L, Dixon M, Massa M, Lally E, Mc Closkey D, Varga J, Ingenito F, Furst D. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
27. Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010, 62:580-588.
28. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver YH, Kim R, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA, Sanders ME, Maranian P, Seibold JR, . Relaxin Investigators and the Scleroderma Clinical Trials Consortium Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:1102-1111. Relaxin Investigators and the Scleroderma Clinical Trials Consortium.
29. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007, 56:1010-1020.
30. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011, 70:104-109.
31. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004, 10:71-84.
32. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005, 77:3-15.
33. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010, 30:245-257.
34. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
35. Meng J, Gong M, Bjorkbacka H, Golenbock DT. Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions. J Immunol 2011, 187:3683-3693.
36. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001, 7:167-202.
37. Kiyokawa T, Akashi-Takamura S, Shibata T, Matsumoto F, Nishitani C, Kuroki Y, Seto Y, Miyake K. A single base mutation in the PRAT4A gene reveals differential interaction of PRAT4A with Toll-like receptors. Int Immunol 2008, 20:1407-1415.
38. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP, Muszynski A, Miyake K, Zhang J, Lee WP, Muszyński A, Forsberg LS, Carlson RW, Dixit VM. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013, 341:1246-1249.
39. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 2013, 341:1250-1253.